Caris Life Sciences

On #NationalDoctorDay, we recognize the impact of all doctors. Dr. Leo Shunyakov, a Medical Oncologist/Hematologist at Central Care Cancer Center, uses precision oncology to help extend lives and improve cancer care. Dr. Shunyakov uses Caris testing to identify driver mutations, predict treatment responses and personalize care. Learn why Caris testing helps improve patient outcomes: https://lnkd.in/gMKywid2

Caris Biopharma Solutions seamlessly blend molecular science and artificial intelligence to push the boundaries of therapy development. Discover the future of healthcare with us. Learn more: https://ow.ly/8xzR50QSic2

Unleash the potential of liquid biopsy with Caris Assure, an innovative multi-cancer assay that provides deep molecular insights from a simple blood sample. Explore how this powerful liquid biopsy assay can revolutionize patient care: https://ow.ly/6XMo50SBG4z

Can molecular profiling improve the classification of endometrial stromal sarcomas (ESS) into low- and high-grade subtypes? Hear Tulio Mateo Silva discuss 238 ESS cases profiled at Caris with DNA & RNA sequencing and IHC. #USCAP2025 ?https://lnkd.in/gAsBDqBR

How can AI help confirm rare cancer diagnoses? Caris GPSai combines machine learning with WES and WTS data to identify tumor origin. In a recent study, Caris GPSai helped diagnose an uncommon primary lung presentation of granulosa cell tumor, a typically ovarian cancer. Learn more: https://lnkd.in/g3rwMs_H

Join Caris at the USCAP - United States and Canadian Academy of Pathology Annual Meeting in Boston, MA. Visit our team at?booth 928?to discover the latest innovations in precision medicine and how our products and services are leading the molecular revolution. Learn more: https://lnkd.in/g27rWsjf

Caris Life Sciences has published a 295,000+ patient study revealing variable efficacy among cancers for patients treated with tissue-agnostic drugs and uncovering the potential for expanding approvals to other drugs in the same class.? ? “By harnessing the power of Caris’ large clinico-genomic dataset, we have shown that tissue-agnostic drugs produce different outcomes in different tissues,” said?George Sledge, Jr., MD, EVP and Chief Medical Officer of Caris and study author. ? Our advanced analyses of real-world data now enable us to uncover findings of clinical value for large patient populations. One in five patients in our study were eligible for a tissue-agnostic drug, which demonstrates the widespread impact of our findings,” said Caris President and study author?David Spetzler, MS, PhD, MBA. ? Learn more:?https://lnkd.in/gcD8WZCj

Join Caris scientific and medical leaders as they discuss MI Cancer Seek, the first and only simultaneous WES/WTS-based assay with CDx indications for adult and pediatric patients (ages 1-22). Presenters will review cases that highlight the strengths of MI Cancer Seek in a clinical workflow. Register Now: https://lnkd.in/dMm7Nqmt Presenters: David Spetzler, MS, MBA, PhD Matthew Oberley, MD, PhD

How can whole transcriptome sequencing uncover potential prognostic biomarkers for patients with cancer? Our poster, presented by Tanvi Joshi, M.D., reports how tumor RNA sequencing revealed that high GPR171 expression is associated with improved survival in cervical cancer. https://lnkd.in/gPfKVsKS

Does it matter which IHC scoring system is used to evaluate HER2 in endometrial carcinoma? Visit Rachel Furuya, M.D.’s poster to discover how gastric and breast criteria perform in endometrial epithelial adenocarcinoma and the potential clinical implications of these results. https://lnkd.in/gPfKVsKS